Reading the tape
NASDAQ: DFTX
Definium Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$2.37B
52w High
$26.15
52w Low
$12.88
P/E
-10.57
Volume
1.06M
Outstanding Shares
109.07M
Price vs Fundamentals
Why The Stock Is Moving
Mixed / unclearLow confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: 232.06%FCF (TTM): -64.89%
What changed
The stock rose 232.06% over the last year. Free cash flow declined 64.89% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or cash flow over the next period would be the clearest signal to resolve the ambiguity.
Company profile
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.
CEORobert Barrow
SectorHealthcare
IndustryBiotechnology
Employees74
IPO dateNov 15, 2016
Valuation
Forward P/E—
EV/EBITDA-5.26
Enterprise value$938.26M
Stock splits
Aug 29, 2022↓ Reverse
Every 15 shares became 1
Mar 3, 2020↓ Reverse
Every 8 shares became 1
Profitability & growth
Revenue growth—
Gross margin0%
Operating margin0%
ROE-55.3%▼22.87%vs FY2024
Analyst consensus
RatingBuy
Target price$35.63▲63.82%
4
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est -$0.47 · Revenue est —
View